HK Stock Market Move | HBM HOLDINGS-B (02142) surged over 8% in early trading; new generation of CTLA-4 antibodies going abroad, total amount may exceed 1.2 billion US dollars.

HBM Holdings-B(02142) rose more than 8% in early trading, and as of the time of writing, it was up 7.92%, at 13.21 Hong Kong dollars, with a trading volume of 21.7947 million Hong Kong dollars. On the news front, on February 23, Hepalink announced that it will grant Solstice Oncology, the global rights outside of Greater China for its new generation CTLA-4 antibody HBM4003. Solstice Oncology will pay over 105 million US dollars as an upfront payment, including 50 million US dollars as an initial payment, 5 million US dollars as near-term payment, and shares worth over 50 million US dollars. In addition, Hepalink will also receive up to 1.1 billion US dollars in milestone payments, as well as tiered sales royalties. Public information shows that Solstice Oncology is a clinical stage biotechnology company jointly founded by multiple top venture capital institutions, and this cooperation is based on the NewCo model.